Ocrevus Zunovo is the first and only twice-a-year, healthcare professional (HCP)-administered approximately 10-minute subcutaneous (SC) injection approved for both these forms of multiple sclerosis, ...

(RTTNews) - ScinoPharm Taiwan (TWSE: 1789) today announced that the U.S. FDA has approved its Glatiramer Acetate Injection, a generic version of Teva's Copaxone, for the treatment of adult patients ...

Please provide your email address to receive an email when new articles are posted on . Genentech announced it received FDA approval for Ocrevus Zunovo to treat patients with relapsing and primary ...

Kesimpta is a medicine used to treat relapsing forms of multiple sclerosis (MS). Relapsing forms of MS include clinically isolated syndrome, relapsing-remitting MS, and active secondary progressive MS ...

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that the Phase III OCARINA II trial evaluating Ocrevus® (ocrelizumab) ...

March 11 (Reuters) - The U.S. FDA has declined to approve Viatris (VTRS.O), opens new tab and Mapi Pharma's once-a-month injection for treating relapsing forms of debilitating neurological condition ...

Roche Holdings AG's (OTC:RHHBY) Phase 3 OCARINA II trial evaluating Ocrevus (ocrelizumab) as a twice-a-year 10-minute subcutaneous injection met its primary and secondary endpoints in patients with ...

The FDA has declined to approve glatiramer acetate (GA) depot in the treatment of relapsing types of multiple sclerosis (MS), issuing a complete response letter (CRL) for the long-acting, injectable ...